Sanders Morris Harris LLC Buys 7,187 Shares of Bristol-Myers Squibb (NYSE:BMY)

Sanders Morris Harris LLC grew its stake in shares of Bristol-Myers Squibb (NYSE:BMYFree Report) by 57.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,644 shares of the biopharmaceutical company’s stock after acquiring an additional 7,187 shares during the quarter. Sanders Morris Harris LLC’s holdings in Bristol-Myers Squibb were worth $1,065,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of BMY. Rathbones Group PLC lifted its position in shares of Bristol-Myers Squibb by 128.6% during the 3rd quarter. Rathbones Group PLC now owns 57,564 shares of the biopharmaceutical company’s stock valued at $3,341,000 after buying an additional 32,379 shares in the last quarter. Clearbridge Investments LLC lifted its position in shares of Bristol-Myers Squibb by 0.4% during the 3rd quarter. Clearbridge Investments LLC now owns 112,446 shares of the biopharmaceutical company’s stock valued at $6,526,000 after buying an additional 459 shares in the last quarter. LPL Financial LLC lifted its position in shares of Bristol-Myers Squibb by 4.6% during the 3rd quarter. LPL Financial LLC now owns 2,026,052 shares of the biopharmaceutical company’s stock valued at $117,592,000 after buying an additional 88,447 shares in the last quarter. Humankind Investments LLC lifted its position in shares of Bristol-Myers Squibb by 5.1% during the 3rd quarter. Humankind Investments LLC now owns 20,243 shares of the biopharmaceutical company’s stock valued at $1,175,000 after buying an additional 991 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Bristol-Myers Squibb by 5.8% during the 3rd quarter. Northern Trust Corp now owns 25,292,711 shares of the biopharmaceutical company’s stock valued at $1,467,989,000 after buying an additional 1,394,158 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on BMY. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. BMO Capital Markets lowered their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Wells Fargo & Company boosted their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. Finally, StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 17th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $60.00.

Check Out Our Latest Stock Analysis on Bristol-Myers Squibb

Bristol-Myers Squibb Trading Up 2.2 %

Bristol-Myers Squibb stock traded up $0.89 during mid-day trading on Friday, hitting $41.93. The company’s stock had a trading volume of 35,830,690 shares, compared to its average volume of 13,967,854. The company has a 50 day moving average of $43.60 and a 200-day moving average of $48.43. The stock has a market cap of $85.00 billion, a PE ratio of -13.53, a P/E/G ratio of 13.89 and a beta of 0.43. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. Bristol-Myers Squibb has a one year low of $39.63 and a one year high of $65.85.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.05 EPS. On average, research analysts anticipate that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 5.72%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is -77.42%.

Bristol-Myers Squibb Company Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Read More

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.